Novotech signs Central Lab Services Agreement with Sonic Clinical Trials
23 June 2017 - 9:00AM
JCN Newswire (English)
SYDNEY, AUS, June 23, 2017 - (ACN Newswire) - Asia Pacific
specialist CRO Novotech announced today it has expanded its
business offering to include central lab services through a
preferred partnership agreement with Sonic Clinical Trials, an
affiliate of international healthcare company, Sonic
Healthcare.
Through this unique partnership, Novotech clients will be able to
select from a wide menu of assays or biomarkers, access a
trial-specific kit assembly service and use a single clinical
trial-dedicated laboratory with a global reach, for priority
processing of clinical trial samples.
Announcing the new partnership, Novotech CEO Dr. John Moller said,
"Novotech has always focused on offering flexible and cost
effective clinical trial solutions. Through our partnership with
Sonic Clinical Trials, our clients will experience a seamless
integration of laboratory services and clinical trial data
management by Novotech. From the start to finish, our clients are
supported by a team of dedicated project managers.
"Another key benefit to our clients is the fact that Sonic Clinical
Trials is pre-audited and an approved Novotech vendor. This removes
our clients' need to undertake their own central lab vendor
assurance - providing a further savings in cost and clinical trial
time."
Sonic Clinical Trials is a registered Research Service Provider
(RSP) with AusIndustry, a division of the Australian Government's
Department of Industry, Innovation and Science.
"Sonic Clinical Trials' RSP status assists our eligible
international clients when accessing the Australian R&D Tax
Incentive Scheme. Research from a recent Frost and Sullivan white
paper revealed that eligible companies can conduct early stage
clinical trials 60% more cheaply in Australia than the USA,"
explained Dr. Moller.
"Novotech's size and Asia Pacific focus allows our clients to enjoy
a direct, hands-on approach to accessing some of the largest
patient pools in the world, but we balance this with providing
global gold-standard central laboratory services and data
management platforms."
About Australian R&D Tax Incentive Scheme
Through the Australian R&D Tax Incentive Scheme, eligible
companies may claim a 43.5% R&D tax refund on eligible R&D
expenditure. For more information about this scheme, see the joint
Novotech / Frost & Sullivan white paper, "Australia: The
preferred destination for early phase clinical trials", Mar. 31,
2017. http://novotech-cro.com/news-events.
About Sonic Clinical Trials
Sonic Clinical Trials is a wholly owned subsidiary of
Australian-owned Sonic Healthcare, one of the world's largest
specialist medical diagnostics companies, employing more than
33,000 people in Australia, New Zealand, the United Kingdom,
Germany, Switzerland, Belgium, Ireland and the USA. Sonic Clinical
Trials is a registered Research Service Provider (RSP) with
AusIndustry which allows it to assist international clients to
register for the Australian R&D Tax Incentive Scheme. To learn
more, please visit www.sonicclinicaltrials.com.au.
About Novotech
Headquartered in Sydney, Novotech is internationally recognised as
the leading regional full-service contract research organisation
(CRO). With a focus on clinical monitoring, Novotech has been
instrumental in the success of hundreds of Phase I - IV clinical
trials in the Asia Pacific region, while it has worldwide reach
through its network of strategic partners.
Novotech provides clinical development services across all clinical
trial phases and therapeutic areas including: feasibility
assessments; ethics committee and regulatory submissions, data
management, statistical analysis, medical monitoring, safety
services, central lab services, report write-up to ICH
requirements, project and vendor management. For more information,
please visit www.novotech-cro.com.
Media:
Digital Mantra Group
Susan Fitzpatrick-Napier
AU: +61 2 8218 2144 / USA: +1 650 798 5238
Email: susan@dmgpr.com
Corporate:
Novotech
Justine Lamond
Marketing & Communications Manager
AU: +61 2 8569 1458
Email: communications@novotech-cro.com
Source: Novotech
Copyright 2017 ACN Newswire . All rights reserved.
Sonic Healthcare (ASX:SHL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sonic Healthcare (ASX:SHL)
Historical Stock Chart
From Apr 2023 to Apr 2024